MondegarAI
SR ONE CAPITAL MANAGEMENT, LP

Q4 2025 · 13F-HR

SR ONE CAPITAL MANAGEMENT, LPholdings as filed

Filed 2026-02-12 · accession 0001193125-26-048808

$706.4M
Reported value
13
Positions
2025-12-31
Period end
View analyzed profile →PRO

The Brief · SR ONE CAPITAL MANAGEMENT, LP · Q4 2025

AI · grounded in 13F

SR ONE CAPITAL MANAGEMENT, LP established a new position in Ultragenyx Pharmaceutical Inc. RARE valued at $3.17M. The fund nearly doubled its stake in Oculis Holding AG OCS, increasing share count by 98.77%. It also accumulated more shares of Zenas BioPharma, Inc ZBIO and trimmed its holding in Mineralys Therapeutics Inc. MLYS by 26.02%.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
98937L105ZBIOZenas BioPharma, Inc$182.9M25.9%5,037,854CommonSOLE
03940C100ACLXGBXArcellx, Inc.$153.0M21.7%2,346,630CommonSOLE
H17182108CRSPCRISPR Therapeutics AG$106.9M15.1%2,038,763CommonSOLE
25056L103DSGNDesign Therapeutics, Inc.$61.2M8.67%6,526,476CommonSOLE
603170101MLYSMineralys Therapeutics Inc.$56.8M8.03%1,563,966CommonSOLE
82835W108SPRYARS Pharmaceuticals, Inc.$46.8M6.62%4,012,903CommonSOLE
68622P109ORICORIC Pharmaceuticals, Inc.$37.8M5.34%4,514,929CommonSOLE
022307102ALMSAlumis Inc.$19.1M2.71%1,959,896CommonSOLE
687604108ORKAOruka Therapeutics, Inc$13.0M1.85%430,330CommonSOLE
H5870P102OCSOculis Holding AG$12.8M1.81%641,022CommonSOLE
29286M105enGene Holdings Inc.$6.8M0.96%747,750CommonSOLE
65487U108NKTXNkarta, Inc.$6.2M0.87%3,333,333CommonSOLE
90400D108RAREUltragenyx Pharmaceutical Inc.$3.2M0.45%137,753CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.